Impact Biomedical (NYSEAMERICAN:IBO) Director Jason Grady Sells 50,000 Shares

Impact Biomedical Inc. (NYSEAMERICAN:IBO) Director Jason Grady sold 50,000 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $0.65, for a total transaction of $32,500.00. Following the completion of the transaction, the director directly owned 250,182 shares in the company, valued at approximately $162,618.30. This represents a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Impact Biomedical Price Performance

IBO stock traded down $0.04 during mid-day trading on Wednesday, hitting $0.58. 180,458 shares of the company were exchanged.

Impact Biomedical Company Profile

Impact Biomedical, Inc (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc, which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.